Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Epic Sciences Receives CAP Accreditation

Epic Sciences Receives CAP Accreditation

Jan 11, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Epic Sciences announced today that its San Diego laboratory has received accreditation from the College of American Pathologists.

Epic markets a platform it calls "no cell left behind," which isolates circulating tumor cells in an unbiased manner, allowing downstream analyses of single CTCs using genomic, proteomic, and morphologic approaches.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

High Numbers Reported for Russian Vaccine

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Masterpiece Microbiome

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

Limited Trust

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

Nucleic Acids Research Papers on Aging Atlas, Human Metagenomes, Drug Repositioning

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

What's Popular?

In Business News

  1. FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

  2. Startup Angstrom Bio Plans Saliva-Based COVID-19 Nucleic Acid Test on Nanopore Sequencing Platform

    Premium

  3. Tempus Gets CE Mark for xT Tumor Sequencing Assay

  4. In Brief This Week: Fluidigm, Centogene, Ginkgo Bioworks, Applied DNA Sciences, More

  5. OpGen Inks $10M Private Placement Agreement

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.